Healthcare entity
market-trends is the sole category represented across all 1 tracked stories. CPI-006 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline.
Last mentioned: Aug 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 1 tracked stories. CPI-006 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.2 for that window. We currently track 1 Healthcare story that mention David Scott Moore, all published on August 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 40 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering David Scott Moore. Shared-story counts are live from our verified record — not editorial picks.
Q2 2026 Earnings Release
Company reported EPS of ($0.19), missing consensus by $0.03.
Ladenburg Thalmann Upgrade
Ladenburg Thalmann upgraded CRVS to ‘strong-buy’.
Weiss Ratings Upgrade
Weiss Ratings upgraded Corvus from ‘sell (e+)’ to ‘sell (d-)’.
Director Insider Purchase
Director David Scott Moore acquired 21,700 shares at $11.53 per share, totaling $250,201.
Wall Street Zen Downgrade
Wall Street Zen downgraded CRVS from ‘hold’ to ‘sell’.
Goldman Sachs Initiates Coverage
Goldman Sachs issued a ‘buy’ rating and a $40.00 target price for Corvus Pharmaceuticals.
Corvus Pharmaceuticals missed Q2 EPS by $0.03, highlighting the financial fragility of early-stage oncology R&D. With no near-term data readouts, the miss draws attention to cash burn and the critical need for clinical progress to justify its $1.17B valuation.
Source: dailypolitical.com · tickerreport.com
David Scott Moore is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
